Combination of therapy and diagnostics
Theranostics
Bavaria is an international leader in the development of imaging and theranostic procedures. This lighthouse is intended to accelerate the clinical testing of these innovations and give the Bavarian population faster access to these new technologies.
In the second phase of funding for the lighthouse, the conditions for the systematic clinical testing of these innovations are to be further improved with the following three fields of action:
Clinical studies & radiopharmaceutical development
- Development, approval and implementation of innovative studies with new radiopharmaceuticals (e.g. CXCR4, FAP, FACBC, Trivehexin)
- Support from the IMPD Office with regulatory requirements, study approvals and manufacturing authorizations
Network & Infrastructure
- Development and support of a radiopharmaceutical network within the six BZKF sites
- IMPD Office as a central advisory and coordination point
- Promotion of start-ups in the field of theranostics
Dosimetry & quantitative imaging
- Standardization and further development of dosimetry procedures
- Harmonization and standardization of image analysis
- Preparation for AI-supported evaluation procedures
- Infrastructure for centralized image data evaluation
Patient information & public relations
- Development of a podcast series for patient education
- Study newsletter for doctors and patients
A concrete goal of this lighthouse is to make innovative imaging and theranostic radiopharmaceuticals available to all BZKF sites and to accelerate the clinical testing of new theranostic and imaging procedures in multicenter studies.
Technical & structural advances
- Procurement of CE-certified dosimetry software
- Preparation for EARL accreditation
- Development of AI-compatible image data formats
- Support for clinical studies by the IMPD Office
- Upgrading the radiochemistry infrastructure to improve the supply of innovative radiopharmaceuticals to the Bavarian population
Planned studies in the new funding period (selection)
- COLPRIT with 68Ga-Pentixafor (production & application)
- SOLACE-BZKF-01 (combination 177Lu-DOTATOC + Olaparib)
REFINE with 18F-FACBC for PSMA-negative prostate cancer
Establishing Bavaria as a theranostics center
- Strengthening university research & translation into the clinic.
- Positioning Bavaria as a leading location for radiopharmaceuticals.
Standardized theranostics & AI-supported evaluation
- Complete standardization of imaging procedures.
- Use of uniformly annotated data for AI & personalized therapy.
Clinical translation & improvement of care
- Rapid translation of research projects into clinical trials.
- Improvement of patient care through innovative procedures.
Integration with other lighthouses & study groups
- Networking with cellular immunotherapy, AI/bioinformatics and local therapy.
- Shared use of radiopharmaceuticals and infrastructure.
Promotion of spin-offs & young talent
- Advising young scientists on start-ups.
- Further training for medical physics and study personnel
